Cargando…
Role of biologics in severe eosinophilic asthma – focus on reslizumab
Within the context of the heterogeneous phenotypic stratification of asthmatic population, many patients are characterized by moderate-to-severe eosinophilic asthma, not adequately controlled by relatively high dosages of inhaled and even oral corticosteroids. Therefore, these subjects can obtain si...
Autores principales: | Pelaia, Girolamo, Vatrella, Alessandro, Busceti, Maria Teresa, Gallelli, Luca, Preianò, Mariaimmacolata, Lombardo, Nicola, Terracciano, Rosa, Maselli, Rosario |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
Dove Medical Press
2016
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4936812/ https://www.ncbi.nlm.nih.gov/pubmed/27445482 http://dx.doi.org/10.2147/TCRM.S111862 |
Ejemplares similares
-
Cellular Mechanisms Underlying Eosinophilic and Neutrophilic Airway Inflammation in Asthma
por: Pelaia, Girolamo, et al.
Publicado: (2015) -
Severe eosinophilic asthma: from the pathogenic role of interleukin-5 to the therapeutic action of mepolizumab
por: Pelaia, Corrado, et al.
Publicado: (2017) -
Benralizumab: From the Basic Mechanism of Action to the Potential Use in the Biological Therapy of Severe Eosinophilic Asthma
por: Pelaia, Corrado, et al.
Publicado: (2018) -
Update on Anticytokine Treatment for Asthma
por: Gallelli, Luca, et al.
Publicado: (2013) -
Pharmacologic rationale underlying the therapeutic effects of tiotropium/olodaterol in COPD
por: Pelaia, Girolamo, et al.
Publicado: (2015)